TG Therapeutics is a publicly owned biopharmaceutical company headquartered in New York. It focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's product pipeline has two therapies in clinical development, TG-1101 and TG-1202.
TG-1101, also known as Ublituximab, is a monoclonal antibody that targets a specific epitope on the B-lymphocyte CD20 antigen. It has been bioengineered to deliver enhanced clinical activity and potency. The product is aimed at treating B-cell proliferative disorders including, Non-Hodgkin's Lymphoma (NHL) and Cronic Lymphocytic Leukemia (CLL). It has also shown effectiveness against autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), as well as the neurological disorder, Multiple Sclerosis (MS). Ublituximab is in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.
TG-1202, also known as Umbrasilib, is an orally available PI3K delta inhibitor. It targets delta isoforms, which is believed to be important in the proliferation and survival of B-cell lymphocytes. Umbrasilib is in Phase 3 clinical development in combination with Ublituximab for patients with hematological malignancies.
TG Therapeutics has several other products in its pipeline, which are at various stages of preclical studies:
A key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldensrom's Macroglobulinemia, a rare B-cell cancer, as well as in some specific cases of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. IRAK4 is also key in regulating immune and inflammatory processes, suggesting that it may be useful in treating autoimmune related disorders.
Anti-PD-L1 & Anti-GITR
Anti-PD-L1 antibodies target programmed cell death ligand 1 (PD-L1). They are designed to block signals permitting effector T-cells to attack cancer. Anti-GITR antibodies target glucocorticoid-induced tumor necrosis factor receptor related protein (GITR). It has shown to amplify the antitumor immune responses in animal models. Pre-clinical research on therapies using a combination of these two antibodies have yielded positive results. The Anti-PD-L1 monoclonal antibody has been brought into Phase 1 of clinical development.
TG-1601 is a small molecule that binds to the epigenetic BET family of bromodomain-containing proteins and inhibits their binding to chromatin. It can increase the sensitivity of tumors to chemotherapy or specific standard of care by resetting the genome in tumor cells. TG-1601 is in pre-clinical development and is being tested in various IND-enabling studies.
Chief Commercial Officer
Michael S. Weiss
Executive Chairman, President, & CEO
Sean A. Power
TG Therapeutics, Inc. Announces Oral Presentation of Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation at 60th American Society of Hematology Annual Meeting and Exposition
TG Therapeutics, Inc.
Documentaries, videos and podcasts